sotagliflozin   Click here for help

GtoPdb Ligand ID: 8312

Synonyms: Inpefa® | LX-4211 | LX4211 | Zynquista®
Approved drug PDB Ligand
sotagliflozin is an approved drug (EMA (2019), FDA (2023))
Compound class: Synthetic organic
Comment: Sotagliflozin is a dual inhibitor of the sodium/glucose cotransporters 1 and 2 (SGLT1/2) [5,8]. SGLT1 and SGLT2 mediate glucose reabsorption, by the kidney and in the gastrointestinal tract respectively.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

sotagliflozin is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 104.45
Molecular weight 424.11
XLogP 3.9
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCOc1ccc(cc1)Cc1cc(ccc1Cl)C1OC(SC)C(C(C1O)O)O
Isomeric SMILES CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@@H]1O[C@H](SC)[C@H]([C@@H]([C@H]1O)O)O
InChI InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
InChI Key QKDRXGFQVGOQKS-CRSSMBPESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Aziri B, Begic E, Jankovic S, Mladenovic Z, Stanetic B, Kovacevic-Preradovic T, Iglica A, Mujakovic A. (2023)
Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.
ESC Heart Fail, 10 (3): 1499-1530. [PMID:36967133]
2. Banerjee M, Pal R, Nair K, Mukhopadhyay S. (2023)
SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
Indian Heart J, 75 (2): 122-127. [PMID:36914068]
3. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN et al.. (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med, 384 (2): 129-139. [PMID:33200891]
4. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M et al.. (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
N Engl J Med, 384 (2): 117-128. [PMID:33200892]
5. Lapuerta P, Zambrowicz B, Strumph P, Sands A. (2015)
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Diab Vasc Dis Res, 12 (2): 101-10. [PMID:25690134]
6. Rodriguez R, Kaluzna SD. (2023)
Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
Am J Health Syst Pharm, 80 (13): 818-826. [PMID:36971375]
7. Verma S, Bhatt DL, Dhingra NK, Steg PG, Szarek M, Davies M, Metra M, Lund LH, Pitt B, SOLOIST Investigators. (2023)
Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure.
J Am Coll Cardiol, 81 (15): 1546-1549. [PMID:37045523]
8. Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F et al.. (2012)
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
Clin Pharmacol Ther, 92 (2): 158-69. [PMID:22739142]